The End Of Generics Mergers? Too Much Effort, No Reward!
Executive Summary
There has been $150bn worth of merger and acquisition activity since 2012 in the generic medicines arena, yet the sector is more fragmented than it was five years ago. CEOs and analysts from the generics sector believe that investor-propelled moves towards greater consolidation have been thwarted by the market agility of smaller companies. And now the cost of M&A has burdened major generics firms with debt.
You may also be interested in...
Generic Drug Pricing Transparency Could Reduce Spending, Study Says
Every $1 reduction in the average reimbursement for a generic prescription would reduce US healthcare spending by $4bn, according to a study from Brookings, which concludes more generic drug pricing information should be selectively available to third-party payers.
After The Cliff: Fewer Patent Expiries Mean Less Savings From Generics
A PwC report on medical cost trends projects that while US health care cost-growth has plateaued, several inflationary factors remain, including a reduction in big-ticket prescription drugs going off-patent. The trend began in 2016 and is expected to continue in 2018.
Generic Industry Consolidating But Still Mysterious
Nearly 2,000 ANDAs remain unclaimed as US FDA begins fee calculations for GDUFA II.